Related references
Note: Only part of the references are listed.Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
Rene Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway
John Fitton et al.
RHEUMATOLOGY (2021)
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
Bernard Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
Janet Pope et al.
ADVANCES IN THERAPY (2020)
Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia
Paul Bird et al.
CLINICAL RHEUMATOLOGY (2020)
Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial
Ronald van Vollenhoven et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry
Nobunori Takahashi et al.
SCIENTIFIC REPORTS (2020)
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland
A. Finckh et al.
RMD OPEN (2020)
Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe
Alison Cave et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
Josef S. Smolen et al.
LANCET (2019)
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
Mark C. Genovese et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution
Kim Lauper et al.
RHEUMATOLOGY (2019)
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study
Desiree van der Heijde et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
George W. Reed et al.
RHEUMATOLOGY AND THERAPY (2019)
Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial
Stanley B. Cohen et al.
LANCET RHEUMATOLOGY (2019)
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Mark C. Genovese et al.
LANCET (2018)
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Gerd R. Burmester et al.
LANCET (2018)
Randomized controlled trials and real-world data: differences and similarities to untangle literature data
Sara Monti et al.
RHEUMATOLOGY (2018)
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Marina Amaral de Avila Machado et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial
Joel Kremer et al.
ANNALS OF INTERNAL MEDICINE (2013)
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data
Jeffrey R. Curtis et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis
Jeffrey R. Curtis et al.
ARTHRITIS RESEARCH & THERAPY (2011)
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2010)
Medication compliance and persistence: Terminology and definitions
Joyce A. Cramer et al.
VALUE IN HEALTH (2008)
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study - Comparison of patients according to their eligibility for major randomized clinical trials
Angela Zink et al.
ARTHRITIS AND RHEUMATISM (2006)
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk -: A multicenter active-surveillance report
JJ Gómez-Reino et al.
ARTHRITIS AND RHEUMATISM (2003)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
